CTI BioPharma Completes Recruitment in PERSIST-1 Pivotal Phase 3 Trial of Pacritinib for Patients with Myelofibrosis
IDC Announces New Winners of HPC Innovation Excellence Awards
The U.S. economy is in decent shape, but we are being even more selective given recent outperformance.
As macro headwinds mount, we would look for a larger valuation discount among consumer cyclical names.
As the risk of increasing inflation looms, the risk/reward opportunity in stocks does not signal a screaming buy to us at this point.